Incannex Healthcare Inc.
IXHL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for IXHL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IXHL
Incannex Healthcare Inc. (IXHL) is a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, with a focus on advancing its lead candidate IHL-42X for obstructive sleep apnea and PSX-001 for other indications. The company holds a strong cash position and no debt as of early 2026, funding its ongoing Phase 2 DReAMzz study and future development.
Key risk: No revenue and operating losses
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2026.
Tracking 3 pipeline candidates · 3 clinical trials for Incannex Healthcare Inc..
Incannex Healthcare Inc. (IXHL) is a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, with a focus on advancing its lead candidate IHL-42X for obstructive sleep apnea and PSX-001 for other indications. The company holds a strong cash position and no debt as of early 2026, funding its ongoing Phase 2 DReAMzz study and future development.
- Cash and equivalents of $74.5M as of 2026-03-31, with no debt [sec].
- Lead candidate IHL-42X has completed a Phase II/III trial (NCT06146101) and is advancing to a Phase 2 DReAMzz study (NCT07635563, recruiting) [catalyst].
- PSX-001 is progressing toward its next clinical phase in 2026 [news].
- Company has not generated revenue and expects to continue incurring operating losses until drug candidates are approved [sec_mda].
- FDA Fast Track Designation has been granted for IHL-42X [news].
What works
- Strong balance sheet with approximately $75M cash and no debt as of March 2026, providing runway well into 2027 [news].
- Two positive Phase 2 programs and FDA Fast Track Designation for IHL-42X de-risk development [news].
- Share repurchase program demonstrates management confidence; 2.1 million shares repurchased for ~$9.1M [sec_mda].
What to weigh
- No revenue generated to date; company expects to continue negative cash flows from operations until drug approval [sec_mda].
- Clinical development costs are uncertain and may vary significantly based on trial scope, regulatory feedback, and patient enrollment [sec_mda].
- If additional capital is needed, equity or debt financing could dilute stockholders or impose restrictive covenants [sec_mda].
From the filings
Quoted directly from source documents.
Cash position and no debt
“it holds approximately $75 million in cash with no debt”
News · March 18, 2026
IHL-42X Phase 2/3 trial completed
“Phase 3 Topline: A Phase II/III, Randomised, Double-Blind Clinical Trial to Determine the Safety and Efficacy of IHL- - NCT: NCT06146101. Status: Completed.”
Catalysts · July 27, 2025
No revenue and expected losses
“We have not generated revenue for the three and nine months end March 31, 2026 and we do not expect to generate material revenues unless and until our drug candidates are approved.”
SEC MD&A · May 15, 2026
Share repurchase program
“urchased 2.1 million shares of our Common Stock under the share repurchase program for aggregate consideration of approximately $9.1 million.”
SEC MD&A · May 15, 2026
Catalyst timeline
- 2026-07-21 · Phase 2 DReAMzz study start — Phase II, randomized, double-blind, multidose crossover trial for IHL-42X in obstructive sleep apnea; currently recruiting.
Risks & what to watch (3)›
Key risks
- No revenue and operating losses — Company has no revenue and expects negative cash flows until drug approval [sec_mda].
- Clinical development uncertainty — Costs and timelines for trials are uncertain and may vary significantly [sec_mda].
- Dilution risk from future financing — If additional capital is raised via equity or debt, stockholder dilution or restrictive covenants may occur [sec_mda].
What to watch
- Enrollment and data from the Phase 2 DReAMzz study (NCT07635563) for IHL-42X [catalyst].
- Progress of PSX-001 into next clinical phase in 2026 [news].
- Cash burn rate and any future capital raises or partnerships [sec_mda].
- Regulatory updates and potential FDA interactions for IHL-42X [news].
Sources: Catalysts · News · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Incannex Healthcare Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Incannex Healthcare Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
93.0 months
D/E 0.07 · 0% dilution
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
14
Total value held
$1.1M
| Holder | Shares | Value |
|---|---|---|
| ghisallo capital management llc | 162,855 | $489K |
| mirae asset global etfs holdings ltd. | 149,857 | $450K |
| advisorshares investments llc | 24,503 | $74K |
| commonwealth equity services, llc | 12,112 | $36K |
| osaic holdings, inc. | 6,376 | $19K |
| morgan stanley | 2,065 | $6K |
| quent capital, llc | 1,928 | $6K |
| jpmorgan chase & co | 825 | $3K |
| barclays plc | 750 | $2K |
| larson financial group llc | 59 | $177 |
Showing top 10 of 14 institutional holders of Incannex Healthcare Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 5.9%
- Days to cover
- 1.1
- Shares short
- 814,576
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IXHL short interestGovernance
Frequently asked questions
What is the AI investment thesis for Incannex Healthcare Inc.?
Incannex Healthcare Inc. (IXHL) is a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, with a focus on advancing its lead candidate IHL-42X for obstructive sleep apnea and PSX-001 for other indications. The company holds a strong cash position and no debt as of early 2026, funding its ongoing Phase 2 DReAMzz study and future development.
What is Incannex Healthcare Inc.'s lead drug candidate?
Incannex Healthcare Inc.'s most advanced tracked candidate is ihl-42x (Phase 2) for Obstructive Sleep Apnea.
Who is the CEO of Incannex Healthcare Inc.?
Mr. Joel Bradley Latham is the chief executive officer of Incannex Healthcare Inc. (IXHL).
Where is Incannex Healthcare Inc. headquartered?
Incannex Healthcare Inc. (IXHL) is headquartered in Sydney, NSW, Australia.
What therapeutic areas does Incannex Healthcare Inc. focus on?
Incannex Healthcare Inc. develops therapies across Neurology, Immunology, Respiratory, Pain, Musculoskeletal, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.